Nexxus Capital Completes its $30 Million Investment in IMMUNOTEC
Nexxus Capital has completed its investment in Immuno Holding, S.A. de C.V., a company that, through its subsidiaries after closing of the transaction (IMMUNOTEC), is focused on the development and commercialization of nutritional supplements through multi-level direct sales channels.
The investment was carried out by Nexus Capital Private Equity Fund VI and Nexxus Capital VI Trust in association with Mauricio Domenzain, who has industry experience in Mexico, the US and other countries as a former executive of a direct selling company.
Domenzain will assume the leadership of the team of executives and collaborators in Mexico, Canada and the US.
IMMUNOTEC’s products are commercialised through multi- level direct sales channels mainly in Mexico, with presence in other countries, including the US and Canada. Among the broad product portfolio that IMMUNOTEC offers is the Immunocal family of products, which is backed up by over 40 years of clinical research and testing.
Among the transaction’s advisors were SMPS Legal S.C., with Jorge San Martín and Federico Scheffler advising Immuno Holdings S.A. de C.V.